Danaher Corporation DHR Moat

Key data

The moat

A biologic drug is licensed as a process, not just a molecule. Under the FDA rule for approved biologics (21 CFR 601.12), a change in equipment or production process with substantial potential to affect the product requires a supplement, and a change to a virus-removal step needs approval before the drug ships. Danaher's bioprocessing business sells what sits inside those steps: cell culture media, chromatography resins, filters and single-use bags. Once a drug is approved on them, the cheaper filter costs a comparability study, a filing and months of risk. Diagnostics runs the same way: a lab with a Beckman Coulter analyzer or a Cepheid system buys the tests that fit it, consumables the 10-K calls "typically critical to the use of the equipment."

The primary moat is switching costs, held with high confidence; the secondary is regulatory, since the regulator is what makes leaving expensive. At the dinner table: Danaher sells the printer and the ink, and the government has signed off on the ink.

The swap test partly fails. Sartorius and Merck KGaA sell into the same validated steps with the same regulatory glue. What is Danaher's own, per its 10-K, is breadth: media, resin, filtration and fill means more places in one recipe it is written in. That is the company's description, not a measured share.

What the moat produces is retention: $20.1 billion of 2025's $24.6 billion in sales came from recurring purchases.

Widening or narrowing

On the same continuing perimeter, the recurring share has climbed from 73.9% in 2018 to 81.9% in 2025, and it held at 83.8% in both first halves of 2025 and 2026.

Recurring share from the FY2020, FY2022, FY2023 and FY2025 Forms 10-K revenue disaggregation as filed; excludes Envista and Veralto; acquisitions included from the year bought.

The pricing that rides on the lock tells a different story:

Price contribution to sales growth, FY2023 to FY2025 Forms 10-K. 2021: Biotechnology 2.0%, Life Sciences 1.5% (FY2022 10-K).

The inflection is pricing. Biotechnology is back where it stood in 2021, inflation passing through rather than power lost. Diagnostics is the crack: the company attributes its 2025 price cut to China's volume-based procurement and reimbursement changes, and sales into China fell 16% in two years. A state buyer setting the price overrides any switching cost.

On the profit pool, the money in a biologic sits with the drug owner; Danaher holds the thinner consumables slice, and it has thinned: Biotechnology operating margin as filed ran 35.9%, 34.3%, 26.6%, 24.9% and 25.6% from 2021 to 2025, with the first uptick last year.

The overrated case: the rising share is partly a shrinking denominator. Biotechnology recurring sales fell 8% from 2022 to 2025 while its equipment sales fell 52%, so the segment's recurring share rose from 79% to 88% on less business, not more. Equipment is where new processes get written in. Rivals also recovered faster: in 2025 Sartorius grew its bioprocess division 9.5% in constant currency and Merck KGaA grew Process Solutions 10.7% organically, against 6.5% core growth for Danaher's Biotechnology segment. Management says bioprocessing orders grew mid-teens in the second quarter of 2026, a claim not yet visible in sales.

The lock holds; pricing and new growth do not widen it. The trajectory is stable.

What breaks it, and who

The first pressure is a rival writing itself into the next generation of processes. Merck KGaA's Process Solutions, the largest rival reporting its bioprocess unit separately at €3.8 billion of 2025 sales, is the number two here, and it is growing faster; Danaher's bioprocessing core growth was low single digits in the second quarter of 2026.

The second is state pricing. Roche's chief executive said its diagnostics sales in China fell 24% in 2025, so the pressure is on the market, not one supplier.

The third is weak equipment demand starving the installed base that feeds future consumables.

Company releases: Merck KGaA 2024 and 2025 annual reports and Q2 2026 results; Sartorius FY2024, FY2025 and H1 2026 releases; bioMérieux FY2024, FY2025 and H1 2026 releases.

The news that would change the read in twelve to eighteen months: bioprocessing core growth closing to rivals' high single digits, Biotechnology equipment sales stopping their fall, or Diagnostics price turning positive.

Closing thoughts

The moat is real and stable: eight of ten dollars repeat and the regulator still makes leaving costly. The pricing on top has not held, back to its 2021 level in Biotechnology and below zero in China. The one checkable thing is Biotechnology equipment sales in the FY2026 10-K, where future lock-ins begin. The moat strengthens if equipment placements recover and bioprocessing core growth matches Merck KGaA and Sartorius; it weakens if recurring dollars keep shrinking while those rivals grow near 10%.